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ABSTRACT
The catechol-O-methyltranferase (COMT) is one of the
main enzymes that metabolise dopamine in the brain.
The Val158Met polymorphism in the COMT gene
(rs4680) causes a trimodal distribution of high (Val/Val),
intermediate (Val/Met) and low (Met/Met) enzyme
activity. We tested whether the Val158Met
polymorphism is a modiﬁer of the age at onset (AAO) in
Parkinson’s disease (PD). The rs4680 was genotyped in
a total of 16 609 subjects from ﬁve independent cohorts
of European and North American origin (5886 patients
with PD and 10 723 healthy controls). The multivariate
analysis for comparing PD and control groups was based
on a stepwise logistic regression, with gender, age and
cohort origin included in the initial model. The
multivariate analysis of the AAO was a mixed linear
model, with COMT genotype and gender considered as
ﬁxed effects and cohort and cohort-gender interaction as
random effects. COMT genotype was coded as a
quantitative variable, assuming a codominant genetic
effect. The distribution of the COMT polymorphism was
not signiﬁcantly different in patients and controls
(p=0.22). The Val allele had a signiﬁcant effect on the
AAO with a younger AAO in patients with the Val/Val
(57.1±13.9, p=0.03) than the Val/Met (57.4±13.9) and
the Met/Met genotypes (58.3±13.5). The difference was
greater in men (1.9 years between Val/Val and Met/Met,
p=0.007) than in women (0.2 years, p=0.81). Thus,
the Val158Met COMT polymorphism is not associated
with PD in the Caucasian population but acts as a
modiﬁer of the AAO in PD with a sexual dimorphism:
the Val allele is associated with a younger AAO in men
with idiopathic PD.
INTRODUCTION
Parkinson’s disease (PD) is a neurodegenerative dis-
order characterised by the loss of dopaminergic
neurons in the mesencephalon. The diagnosis of
PD is usually made when patients ﬁrst notice symp-
toms of motor dysfunction (bradykinesia, tremor
and rigidity) that are related to loss of
the dopaminergic innervation in the striatum.
However, the dopaminergic deﬁciency in the
mesencephalon remains clinically silent until
the concentration of dopamine has decreased by
60–80% in the striatum, and until 30–40% loss of
dopaminergic neurons has been reached (1–7).
Compensatory mechanisms may thus be involved
to explain this delay in the occurrence of motor
symptoms.
In the central nervous system, two main
enzymes, the monoamine oxidase B (MAOB) and
the catechol-O-methyltranferase (COMT) metabol-
ise dopamine. The human COMT gene (OMIM
116790) is localised on chromosome 22q11.2. The
distribution of COMT activity in the population
and in families indicates that it is regulated by a
single autosomal locus with two codominant
alleles.1 2 The substitution of valine (Val) by
methionine (Met) at codon 158 (Val158Met) in the
membrane-bound isoform, corresponding to codon
108 in the soluble form, results in a trimodal distri-
bution of high, low and intermediate enzymatic
activity. COMT activity is threefold to fourfold
higher in the liver and red blood cells of 158Val
patients than in those with the 158Met variant.3 4
There are ethnic differences in the distribution of
the Val158Met genotype.5 About 25% of the
Caucasian population is homozygous for the low
activity variant (Met/Met), 25% is homozygous for
the high activity variant (Val/Val) and 50% has the
intermediate activity variant (Val/Met).6
The inﬂuence of the COMT Val158Met poly-
morphism on non-motor symptoms in PD, particu-
larly cognitive functions, has been studied7–11
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but little is known about its effect on motor symptoms. In the
present study, we hypothesise that COMT activity might modu-
late the age at onset (AAO) of motor symptoms in PD by modi-
fying the bioavailability of the remaining endogenous dopamine
in the striatum. Using the COMT Val158/108Met polymorph-
ism as a surrogate marker of enzyme activity, we performed an
association study in 16 609 patients and controls of European
and North American origin.
PATIENTS AND METHODS
French samples
Subjects with PD (n=1031) were recruited through the French
network for the study of Parkinson’s disease genetics associating
15 university hospitals across France. All patients were of
European origin. Deﬁnite and probable PD was deﬁned accord-
ing to the UK Parkinson’s Disease Society Brain Bank
(UKPDSBB).12 The healthy controls (n=2061) of the French
sample came from either the French Three-City (3C) cohort
(n=1933)13 or the Parkinson’s disease genetics network
(n=128). The participants of the 3C cohort were non-
institutionalised subjects over 65 years of age, randomly selected
from the electoral rolls of three French cities. The control sub-
jects were matched for gender with patients with PD.
German samples
The German samples consisted of three independent cohorts
(Kiel, Lübeck and Tübingen). Patients with PD (n=648) and
healthy controls (n=688) from the Kiel sample were from the
Population Based Assessment of Genetic Risk Factors for PD
study performed in northern Germany in cooperation with the
Populationsgenetik (POPGEN) biobank.14 All participating
patients with PD were diagnosed by board certiﬁed neurologists
according to the UKPDSBB Criteria.12 Controls (n=688), also
obtained by POPGEN, were matched to the cases by gender and
geographical origin and were screened to conﬁrm the absence
of PD. The Lübeck sample consisted of 525 cases and 223
healthy controls collected in specialised outpatient clinics. All
patients underwent a detailed neurological examination by a
movement disorder specialist and the diagnosis of PD was estab-
lished clinically according to the UKPDSBB.12 The controls
underwent the same neurological examination as the patients.
The PD cases (n=662) for the Tübingen cohort were collected
by movement disorders specialists at the Universities of Munich
and Tübingen, according to the UKPDSBB.12 Sample collection
from controls (n=767) was performed as part of the
Prospective validation of risk markers for the development of
idiopathic Parkinson’s disease (Idiopathic Parkinson Kohorte
Syndroms, PRIPS) study in Tübingen.
International Parkinson’s Disease Genomics Consortium
Genome-wide association studies-based data from three contribut-
ing cohorts from the International Parkinson’s Disease Genomics
Consortium was used in this study and have been described in
detail elsewhere.15 16 This includes 937 cases of PD and 3033 con-
trols from the US samples from the National Institute on Aging
cohort, 744 cases and 2019 controls from the Dutch cohort, and
1648 cases and 2699 controls from the UK cohort.17–19
All these studies were carried out in accordance with the
Declaration of Helsinki and the rules for clinical good practice.
All participants gave their informed consent. The local Ethical
Committees approved the studies.
AAO deﬁnition
AAO was systematically determined at the time of inclusion
by a retrospective interview. The AAO was deﬁned as the ﬁrst
PD-related motor symptom (akinesia, tremor or rigidity) experi-
enced by the patient for the French, Lübeck and Tübingen
cohorts, and by the age at which PD was ﬁrst diagnosed for the
Kiel sample and the International Parkinson’s Disease Genomics
Consortium cohorts.
Genotyping
The COMT polymorphism G185A (rs4680) was analysed by an
allelic discrimination Taqman assay (Applied Biosystems PRISM
7900 sequence detection system, Applied Biosystems, Foster
City, USA) for the German samples or extracted from DNA
array studies as described elsewhere.15 16 20–24
Statistical analysis
Descriptive statistics used numbers and percentages as qualita-
tive variables and means and SDs as quantitative variables.
Relationships between qualitative variables were tested using
χ2 tests and comparisons between means of quantitative vari-
ables were performed using Student t tests for two groups and
unbalanced analysis of variance (ANOVA) for more than two
groups. The multivariate analysis for comparing PD and control
groups was based on a stepwise logistic regression, with all vari-
ables included in the initial model and variables statistically sig-
niﬁcant with p<0.05 by the Wald test retained in the ﬁnal
model. The multivariate analysis of the AAO was ﬁrst based on
a mixed linear model, with the COMT genotype and gender
considered as ﬁxed effects and cohort and cohort-gender inter-
action considered as random effects. In a second step, two dis-
tinct models were ﬁtted, one for men and one for women, with
the COMT genotype as the ﬁxed effect and the cohort as the
random effect. In all mixed linear models, the COMT genotype
was coded as a quantitative variable, namely as the number of
‘L’ alleles. Hardy-Weinberg equilibrium was tested using χ2 tests
in each sample. All tests were two-sided, with a p value of 0.05
considered statistically signiﬁcant. Computations were per-
formed using the SAS V.9 statistical package.
RESULTS
Characteristics of patients and controls
A total of 17 665 subjects were available (6177 patients with PD
and 11 488 controls). Due to insufﬁcient DNA quantity or
quality or missing clinical information 1056 specimens were
excluded for further analysis. Finally, 16 609 subjects were
genotyped for the rs4680 polymorphism and included in the
analysis (5886 patients with PD and 10 723 healthy controls).
Table 1 Characteristics of subjects
PD Controls
n Sex ratio AAO n Sex ratio Age at inclusion
All 5886 1.5 57.6±13.8 10723 1.01 60.0±10.1
US 937 1.5 57.8±13.2 3033 0.89 63.3±10.1
UK 1648 1.4 64.2±12.4 2699 1.07 53.0±0.0
NL 744 1.8 55.6±11.8 2019 0.79 55.7±5.8
France 1031 1.3 48.4±13.2 2061 1.20 73.0±6.4
Germany 1526 1.5 57.4±13.0 911 1.14 50.2±15.7
AAO, age at onset; n, number of subjects; NL, Netherlands; Sex ratio, male/female;
PD, Parkinson’s disease; US, North-American.
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The characteristics of subjects in the ﬁve cohorts are summarised
in table 1. The mean AAO for patients with PD was
57.6±13.8 years. Cohorts of patients with PD were signiﬁcantly
different in terms of AAO (p<0.001) and sex ratio (p=0.04).
The mean AAO was also signiﬁcantly different between gender
(male 57.1±13.7, female 58.3±13.9, p=0.001). Subsequent
analyses thus included gender and cohorts in the multivariate
model.
Distribution of the COMT polymorphism
The distribution of the Val158Met polymorphism in the dataset
is described in table 2. The distribution of the single nucleotide
polymorphism (SNP) was in Hardy-Weinberg equilibrium in
patients (p=0.44) and controls groups (p=0.25). The distribu-
tion of genotypes (Val/Val, Val/Met and Met/Met) was similar
and not signiﬁcantly different in patients and controls (table 2,
p=0.22). However, genotype distributions differed signiﬁcantly
among cohorts (p<0.001). The multivariate analysis including
gender, cohorts and the age of PD and controls in the model
found no signiﬁcant association between the Val158Met poly-
morphism and PD (p=0.22). Altogether, these results failed to
ﬁnd an association between rs4680 and PD in a large popula-
tion of Caucasian patients with PD and controls.
AAO and COMT polymorphism
The AAO was analysed assuming a genetic codominant model
for the Val158Met COMT polymorphism in accordance with its
codominant effect on the enzyme activity. A signiﬁcant differ-
ence of AAO was found for the French (47.9±13.3 for Val/Val
compared with 50.2±13.1 for Met/Met, p=0.04) and the US
samples (56.2±13.4 for Val/Val compared with 59.5±12.7 for
Met/Met, p=0.03). For the UK, Dutch and German samples no
signiﬁcant changes could be found (data not shown).
The univariate analysis for the whole PD sample (n=5886)
found a signiﬁcant difference of AAO according to genotype
with an earlier AAO for those carrying the Val158 allele, corre-
sponding to the high enzyme activity (table 3, p=0.04). The
multivariate analysis conﬁrmed the signiﬁcant association of the
AAO with the COMT polymorphism when cohorts and gender
were included in the model (p=0.03). The difference of AAO
was 1.2 years earlier for patients with the Val/Val genotype com-
pared with patients with the Met/Met genotype (57.1±13.9 vs
58.3±13.5, p=0.017). Interestingly, this difference was
higher in male patients (56.0±14.1 for Val/Val compared with
57.9±13.6 for Met/Met, p=0.007) than in female patients
(58.6±13.4 for Val/Val compared with 58.8±13.3 for Met/Met,
p=0.81) (table 3).
DISCUSSION
This is the largest study in which the COMT polymorphism
rs4680 (Val158Met) was genotyped in PD in 16 609 patients
and controls from different European and North American
samples. We show that the rs4680 polymorphism is a genetic
modiﬁer of the AAO in patients with idiopathic PD. Our results
suggest a codominant effect of the COMT Val158Met poly-
morphism resulting in a modiﬁcation of the AAO by 1.2 years
between extreme genotypes (Val/Val and Met/Met). This effect
was signiﬁcant in men but not in women with a 1.9 years differ-
ence between extreme genotypes in men. This modifying effect
was not associated with an increased risk of PD associated with
the Val158Met polymorphism. This result conﬁrms, in a larger
cohort, the absence of association between this polymorphism
and PD risk in the Caucasian population.7 25–27 In the French
and US samples we revealed a signiﬁcant earlier AAO associated
with the Val/Val genotypes. In the remaining samples from
Germany, the Netherlands and the UK no signiﬁcant result has
been shown. A possible explanation might be that these samples
were underpowered.
The effect of the COMT Val158Met polymorphism on AAO
might be explained by a difference of metabolism of the
endogenous dopamine in the striatum at disease onset. Indeed,
patients carrying the Val158 allele (Val/Val and Val/Met) may
have a reduced dopamine bioavailability because of a higher
enzyme activity leading to earlier motor symptoms. Conversely,
poor metabolisers (Met/Met) may have a greater dopamine bio-
availability delaying their motor symptoms. The inverse U curve
effect of dopamine concentration in the frontal cortex28 was
elegantly validated in studies of working memory in healthy
controls and schizophrenic patients demonstrating that the
Val158Met COMT polymorphism has indeed functional conse-
quences on brain function.29 30 In PD, studies on the impact of
the Val158Met polymorphism on non-motor symptoms have
produced conﬂicting results.7–11 No evidence was found for an
association between the Val158Met genotype and daytime
sleepiness or on neuropsychological measures of attention and
executive function.9 10 Other studies showed that the genotype
directly affects executive function in early stage PD; Val/Val
patients have less frontoparietal activation on fMRI11 and better
performance on executive tasks.8 11 A pharmacogenetic study
showed that the COMT polymorphism determines the acute
response to entacapone,31 although the motor response to levo-
dopa alone was not modiﬁed by the COMT polymorphism.31 32
These results collectively show that the COMT polymorphism
modiﬁes the PD phenotype. Considering its frequency, it might
have to be taken into account in the clinical management of
patients with PD.
An interesting result in our study was the gender difference of
the COMT genotype effect on AAO. The AAO was not signiﬁ-
cantly different in women whereas it was 1.9 years earlier in men
Table 2 Distribution of the COMT Val158Met polymorphism in PD
and controls
Total (% (n)) Control (% (n)) PD (% (n)) p Value
Val/Val 23.7 (3943) 23.6 (2526) 24.1 (1417) 0.22
Val/Met 49.5 (8214) 49.5 (5303) 49.5 (2911)
Met/Met 26.8 (4452) 27.0 (2894) 26.5 (1558)
Val/Val: homozygous for the Val158 allele; Val/Met: heterozygous; Met/Met:
homozygous for the Met158 allele. p Value: multivariate analysis (see material and
methods).
COMT, catechol-O-methyltranferase; PD, Parkinson’s disease.
Table 3 Age at onset in patients with PD according to COMT
Val158Met genotype
Met/Met Val/Met Val/Val
Univariate
p value
Multivariate
p value
Total 58.3±13.5 57.4±13.9 57.1±13.9 0.041 0.026*
Men 57.9±13.6 57.1±13.6 56.0±14.1 0.013 0.007**
Women 58.8±13.3 57.7±14.3 58.6±13.4 0.29 0.81**
*Multivariate model including cohorts and gender as cofactors.
**Multivariate model including cohorts as cofactor.
Val/Val: homozygous for the Val158 allele; Val/Met: heterozygous; Met/Met:
homozygous for the Met158 allele.
COMT, catechol-O-methyltranferase; PD, Parkinson’s disease.
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with the Val/Val genotype compared with the Met/Met genotype.
A sexually dimorphic autosomal genetic association of the
COMT gene has been well-recognised in psychiatric disorders
but has not yet been described in PD. One of the best-replicated
ﬁndings was the association of low enzymatic activity with
obsessive-compulsive disorder in men, but not in women.33–35 In
postmortem studies, the dorsolateral prefrontal cortex of women
had lower COMT activity than men.36 Further evidence
for gender differences comes from COMT knockout mice
(COMT-/-).37 In this model dopamine levels in the frontal cortex
are signiﬁcantly increased in male COMT-/- mice compared with
wild-type mice, but not in female COMT -/- mice. Sex hormones,
especially oestrogen, probably contribute to explain gender dif-
ferences. Oestrogens inhibit COMT mRNA expression in cells
expressing oestrogen receptors.38 However the oestrogen
hypothesis might only be a part of the explanation of the gender
dimorphism in our study because (1) oestrogen levels fall in post-
menopausal women, the age at which PD commonly occurs and
(2) in mid-age men the COMT protein and activity levels rise
considerably,39 despite steady oestradiol levels within this
period.40 Bearing this in mind further pathophysiological mech-
anism could be responsible for the sexual dimorphism like add-
itional gene implication or epigenetic regulation.41 A candidate
gene involved in gender differences could be the monoamine
oxidase B (MAOB; OMIM 309860), an X linked gene, which also
participates in dopamine metabolism. The MAOB brain activity
increases with age42 and its activity is regulated by epigenetic
factors.43 Different SNPs of the MAOB44 and the combination of
genotypes at risk for the MAOB and the COMT gene45 were sus-
pected to be associated with PD. Interestingly, one MAOB SNP
(rs1799836) was available in French patients with PD (n=992).
In this subset, no signiﬁcant association was found between AAO
and this MAOB SNP either alone or in combination with the
COMTrs4680 (data not shown).
Our study may have some limitations although statistical biases
were carefully avoided by performing multivariate analyses
adjusting for cohort origin and gender. Because non-motor—and
non-dopaminergic symptoms—may precede motor symptoms in
PD, disease onset might not adequately reﬂect dopaminergic
denervation in the striatum that might be modiﬁed by the
COMT. Finally, other environmental modiﬁers, like tobacco, are
also likely to contribute to the development of PD symptoms but
environmental factors were not available in our dataset. Genetic
forms of PD as well as genetic susceptibility factors such as muta-
tions in the galactocerebrosidase gene were not systematically
screened. Indeed, an association between heterozygous galacto-
cerebrosidase gene mutation and the AAO has been suspected in
PD.46 Future studies must integrate the effects of environmental
and genetic factors, including the COMT polymorphism, that
could affect the bioavailability of dopamine in general, and espe-
cially in individuals at risk for PD.
In conclusion, our data indicate that the COMT polymorph-
ism rs4680 (Val158Met) is a genetic modiﬁer of AAO in patients
with PD, with a higher effect in male patients than in female
patients. This may be important for future diagnostic and thera-
peutic strategies.
Author afﬁliations
1INSERM, UMR_S975, CR-ICM, Paris, France
2UPMC University Paris 06, UMR_S975, CR-ICM, Pitié-Salpêtrière Hospital, Paris,
France
3CNRS UMR 7225, CR-ICM, Pitié-Salpêtrière Hospital, Paris, France
4Assitance Publique Hôpitaux de Paris, Département de Génétique et Cytogénétique,
Hôpital de la Pitié-Salpêtrière, Paris, France
5INSERM, CIC-9503, Hôpital de la Pitié-Salpêtrière, Paris, France
6Assistance Publique Hôpitaux de Paris, Department of Neurology, Hôpital de la
Pitié-Salpêtrière, Paris, France
7Department of Neurology, University Hospital Würzburg, Würzburg, Germany
8Assistance Publique Hôpitaux de Paris, Department of Biostatistics, Hôpital de la
Pitié-Salpêtrière, Paris, France
9Laboratory of Neurogenetics, National Institute on Aging, National Institutes of
Health, Bethesda Maryland, USA
10INSERM U1043, CPTP, Toulouse, France
11Paul Sabatier University, Toulouse, France
12Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK
13Department of Clinical Genetics Section of Medical Genomics, VU Medical Center,
Amsterdam, Netherlands
14Institute of Experimental Medicine, Christian-Albrechts University, Kiel, Germany
15Assistance Publique Hôpitaux de Paris, Department of Pharmacology, Hôpital de la
Pitié-Salpêtrière, Paris, France
16Faculté de Médecine de Tunis, Université de Tunis El Manar, Centre National de
Pharmacovigilance de Tunis, Service de Pharmacologie Clinique, Tunis, Tunisia
17Institute of Neurogenetics, University of Lübeck, Lübeck, Germany
18Department of Neurodegenerative Diseases, Hertie-Institute for Clinical Brain
Research, University of Tübingen, Tübingen, Germany
19Department of Neurodegenerative Diseases, German Center for Neurodegenerative
Diseases (DZNE), Tübingen, Germany
20Department of Neurology, UKS-H, Campus Kiel; Christian-Albrechts-University,
Kiel, Germany
21Hôpital Gabriel Montpied, CHU de Grenoble, Department of Neurology, Clermont-
Ferrand, France
22CHU de Grenoble, Department of Neurology, Grenoble, France
23CHU de Nantes, Centre d'Investigation Clinique, Nantes, France
24 Hôpital Haut-Lévêque, Department of Neurology, Pessac, France
25INSERM, U744, Lille, France
26Institut Pasteur de Lille, Lille, France
27Université Lille-Nord de France, Lille, France
28Université Pierre et Marie Curie—Paris 6, CNRS 7225 CRICM, ER4-UPMC
Modélisation en recherche clinique, Hôpital Pitié-Salpêtrière, Paris, France
29INSERM UMR_S708, Neuroépidémiologie, Paris, France
30INSERM U897, Université Bordeaux Ségalen, Bordeaux, France
31
“Movement Disorders and Basal Ganglia: Pathophysiology and experimental
Therapeutics”, INSERM, UMR_S975, Paris, France
Acknowledgements We thank all study participants for their cooperation.
The technical assistance of the DNA and cell bank of the Federative Institute for
Neuroscience is gratefully acknowledged and the authors wish to thank Dr Merle
Ruberg for critical review of the manuscript. We also thank the members of the
French 3C Consortium: Annick Alpérovitch, Claudine Berr, Christophe Tzourio and
Philippe Amouyel for allowing us to use part of the 3C cohort. This study was
supported by grants from the German Federal Ministry of Education and Research
(01GI0201), the Medical Faculty of the Kiel University, the Cluster of Excellence
‘‘Inﬂammation at Interfaces,’’ Christian-Albrechts University, Kiel, Ministry for
Science, Commerce and Transportation of Schleswig-Holstein, Germany, and the
German National Genome Research Network (NGFN) through the POPGEN biobank
(BMBF 01GR0468). CK is a recipient of a career development award from the
Hermann and Lilly Schilling Foundation. The US work was supported in part by the
Intramural Research Programs of the National Institute on Aging project numbers
Z01 AG000949-02. Portions of this study used the high-performance computational
capabilities of the Biowulf Linux cluster at the National Institutes of Health,
Bethesda, Md. (http://biowulf.nih.gov).
Collaborators The French Parkinson’s Disease Genetics Study Group includes,
Y Agid: AP-HP, Hôpital de la Pitié-Salpêtrière, Department of Neurology, 75013
Paris, France; M Anheim: AP-HP, Hôpital de la Pitié-Salpêtrière, Département de
Génétique et Cytogénétique, Centre de Génétique Moléculaire et Chromosomique,
75013 Paris, France; A-M Bonnet: AP-HP, Hôpital de la Pitié-Salpêtrière, Department
of Neurology, 75013 Paris, France; M Borg: Service de Neurologie, Hôpital Pasteur,
Nice, France; A. Brice: AP-HP, Hôpital de la Pitié-Salpêtrière, Department of
Neurology, 75013 Paris, France, AP-HP, Hôpital de la Pitié-Salpêtrière, Département
de Génétique et Cytogénétique, Centre de Génétique Moléculaire et
Chromosomique, 75013 Paris, France; E Broussolle: University of Lyon; Hospices
Civils de Lyon, Neurological Hospital, Lyon, France; J-C Corvol: INSERM, Centre
d’Investigation Clinique CIC-9503, Hôpital de la Pitié-Salpêtrière, Paris, France;
Ph. Damier: CHU Nantes, CIC0004, Department of Neurology, Nantes, France;
+A. Destée: University Lille-Nord de France, CHRU de Lille, Neurologie, Hôpital
Roger Salengro, Lille Cedex, France; A Durr: AP-HP, Hôpital de la Pitié-Salpêtrière,
Département de Génétique et Cytogénétique, Centre de Génétique Moléculaire et
Chromosomique, 75013 Paris, France; F Durif: Hôpital Gabriel Montpied,
Department of Neurology, Clermont-Ferrand, France; S Klebe: AP-HP, Hôpital de la
Pitié-Salpêtrière, Département de Génétique et Cytogénétique, Centre de Génétique
Moléculaire et Chromosomique, 75013 Paris, France; E Lohmann: AP-HP, Hôpital de
Klebe S, et al. J Neurol Neurosurg Psychiatry 2013;84:666–673. doi:10.1136/jnnp-2012-304475 669
Movement disorders
 group.bmj.com on June 6, 2013 - Published by jnnp.bmj.comDownloaded from 
la Pitié-Salpêtrière, Département de Génétique et Cytogénétique, Centre de
Génétique Moléculaire et Chromosomique, 75013 Paris, France; M Martinez:
INSERM U563, CPTP, Toulouse, France; C Penet: INSERM, U975, 75013 Paris,
France; P Pollak: CHU de Grenoble, Department of Neurology, Grenoble, France;
P Krack: CHU de Grenoble, Department of Neurology, Grenoble, France; O Rascol:
Departments of Clinical Pharmacology and Neurosciences, Hospital and University
Paul Sabatier of Toulouse, France; F Tison: Hôpital Haut-Lévêque, Department of
Neurology, Pessac, France; C Tranchant: Department of Neurology, Hôpital Civil,
Strasbourg, France; M Vérin: Service de Neurologie, Hôpital Pontchaillou, CHU de
Rennes, Rennes, France; F Viallet: Service de Neurologie, CHU La Timone, Marseille,
France and M Vidailhet: AP-HP, Hôpital de la Pitié-Salpêtrière, Department of
Neurology, 75013 Paris, France. International Parkinson’s Disease Genomics
Consortium (IPDGC) includes—Michael A Nalls: Laboratory of Neurogenetics.
National Institute on Aging, National Institutes of Health, Bethesda, MD 20892,
USA; Vincent Plagnol: UCL Genetics Institute, Gower Place, London, WC1E 6BT, UK;
Jose M Bras: Department of Molecular Neuroscience, UCL Institute of Neurology,
Queen Square, London, WC1N 3BG; Dena G Hernandez: Laboratory of
Neurogenetics. National Institute on Aging, National Institutes of Health, Bethesda,
MD 20892, USA, Department of Molecular Neuroscience, UCL Institute of
Neurology, Queen Square, London, WC1N 3BG; Manu Sharma: INSERM UMR 1043,
CPTP, Toulouse, France; Una-Marie Sheerin: Department of Molecular Neuroscience,
UCL Institute of Neurology, Queen Square, London, WC1N 3BG; Mohamad Saad:
INSERM UMR 1043, CPTP, Toulouse, France, Paul Sabatier University, Toulouse,
France; Javier Simón-Sánchez: Department of Clinical Genetics, Section of Medical
Genomics, VU University Medical Centre, Amsterdam, The Netherlands; Claudia
Schulte: Department for Neurodegenerative Diseases, Hertie Institute for Clinical
Brain Research, University of Tübingen, and DZNE, German Center for
Neurodegenerative Diseases, Tübingen, Germany; Suzanne Lesage: INSERM,
UMR_S975 (Formerly UMR_S679), Paris, France, Université Pierre et Marie
Curie-Paris, Centre de Recherche de l’Institut du Cerveau et de la Moelle épinière,
UMR-S975, Paris, France, CNRS, UMR 7225, Paris, France; Sigurlaug
Sveinbjörnsdóttir: Department of Neurology, Landspítali University Hospital,
Reykjavík, Iceland, Department of Neurology, MEHT Broomﬁeld Hospital,
Chelmsford, Essex, UK, Queen Mary College, University of London, London, UK;
Philippe Amouyel: 51INSERM U744, Lille, France, Institut Pasteur de Lille, Université
de Lille Nord, Lille, France; Sampath Arepalli: Laboratory of Neurogenetics. National
Institute on Aging, National Institutes of Health, Bethesda, MD 20892, USA; Gavin
Band: Wellcome Trust Centre for Human Genetics, Roosevelt Drive, Oxford OX3 7LJ,
UK; Roger A Barker: Department of Neurology, Addenbrooke’s Hospital, University
of Cambridge, Hills Road, Cambridge CB2 2QQ; Céline Bellinguez: Wellcome Trust
Centre for Human Genetics, Roosevelt Drive, Oxford OX3 7LJ, UK; Yoav
Ben-Shlomo: Department of Social Medicine, Bristol University; Henk W Berendse:
Department of Neurology and Alzheimer Center, VU University Medical Center,
Amsterdam, The Netherlands; Daniela Berg: Department for Neurodegenerative
Diseases, Hertie Institute for Clinical Brain Research, University of Tübingen, and
DZNE, German Center for Neurodegenerative Diseases, Tübingen, Germany; Kailash
Bhatia: Department of Motor Neuroscience, UCL Institute of Neurology, Queen
Square, London WC1N 3BG; Rob MA de Bie: Department of Neurology, Academic
Medical Center, University of Amsterdam, Amsterdam, The Netherlands; Alessandro
Bifﬁ: Center for Human Genetic Research, Massachusetts General Hospital, Boston,
MA 02114, USA, Department of Neurology, Massachusetts General Hospital,
Boston, MA 02114, USA, Program in Medical and Population Genetics, Broad
Institute, 7 Cambridge Center, Cambridge, MA 02139, USA; Bas Bloem:
Department of Neurology, Radboud University Nijmegen Medical Centre, Nijmegen,
The Netherlands; Zoltan Bochdanovits: Department of Clinical Genetics, Section of
Medical Genomics, VU University Medical Centre, Amsterdam, The Netherlands;
Michael Bonin: Department of Medical Genetics, Institute of Human Genetics,
University of Tübingen, Tübingen, Germany; Kathrin Brockmann: Department for
Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of
Tübingen, and DZNE, German Center for Neurodegenerative Diseases, Tübingen,
Germany; Janet Brooks: Laboratory of Neurogenetics. National Institute on Aging,
National Institutes of Health, Bethesda, MD 20892, USA; David J Burn: Newcastle
University Clinical Ageing Research Unit, Campus for Ageing and Vitality Newcastle
upon Tyne NE4 5PL UK; Gavin Charlesworth: Department of Molecular
Neuroscience, UCL Institute of Neurology, Queen Square, London, WC1N 3BG;
Honglei Chen: Epidemiology Branch, National Institute of Environmental Health
Sciences, National Institutes of Health, North Carolina, USA; Patrick F Chinnery:
Neurology M4104, The Medical School, Framlington Place, Newcastle upon Tyne,
NE2 4HH UK; Sean Chong: Laboratory of Neurogenetics. National Institute on
Aging, National Institutes of Health, Bethesda, MD 20892, USA; Carl E Clarke:
School of Clinical and Experimental Medicine, University of Birmingham, Edgbaston,
Birmingham B15 2TT, Department of Neurology, City Hospital, Sandwell and West
Birmingham Hospitals NHS Trust, Dudley Road, Birmingham B18 7QH; Mark R
Cookson: Laboratory of Neurogenetics. National Institute on Aging, National
Institutes of Health, Bethesda, MD 20892, USA; J Mark Cooper: Department of
Clinical Neurosciences, UCL Institute of Neurology, Royal Free Campus, Rowland Hill
Street, London NW3 2PF; Jean Christophe Corvol: INSERM, UMR_S975 (Formerly
UMR_S679), Paris, France, Université Pierre et Marie Curie-Paris, Centre de
Recherche de l’Institut du Cerveau et de la Moelle épinière, UMR-S975, Paris,
France, CNRS, UMR 7225, Paris, France, INSERM CIC-9503, Hôpital
Pitié-Salpêtrière, Paris, France; Carl Counsell: University of Aberdeen, Division of
Applied Health Sciences, Population Health Section, Polwarth building, Foresterhill,
Aberdeen, AB25 2ZD; Philippe Damier: CHU Nantes, CIC0004, Service de
Neurologie, Nantes, France; Jean-François Dartigues: INSERM U897, Université
Victor Segalen, Bordeaux, France; Panos Deloukas: Wellcome Trust Sanger Institute,
Wellcome Trust Genome Campus, Hinxton, Cambridge CB10 1SA, UK; Günther
Deuschl37, 37Klinik für Neurologie, Universitätsklinikum Schleswig-Holstein, Campus
Kiel, Christian-Albrechts-Universität Kiel, Kiel, Germany; David T Dexter: Parkinson’s
Disease Research Group, Faculty of Medicine, Imperial College London, 4th Floor,
Burlington Danes Building, Hammersmith Hospital, Du Cane Road, W12 0NN
London, UK; Karin D van Dijk: Department of Neurology and Alzheimer Center,
VU University Medical Center, Amsterdam, The Netherlands; Allissa Dillman:
Laboratory of Neurogenetics. National Institute on Aging, National Institutes of
Health, Bethesda, MD 20892, USA; Frank Durif: Service de Neurologie, Hôpital
Gabriel Montpied, Clermont-Ferrand, France, Alexandra Dürr: INSERM, UMR_S975
(Formerly UMR_S679), Paris, France, Université Pierre et Marie Curie-Paris, Centre
de Recherche de l’Institut du Cerveau et de la Moelle épinière, UMR-S975, Paris,
France, CNRS, UMR 7225, Paris, France, AP-HP, Pitié-Salpêtrière Hospital,
Department of Genetics and Cytogenetics, Paris, France; Sarah Edkins: Wellcome
Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge CB10
1SA, UK; Jonathan R Evans: Cambridge Centre for Brain Repair, Forvie Site,
Robinson Way, Cambridge CB22PY, UK; Thomas Foltynie: Institute of Neurology,
University College London, London, UK; Colin Freeman: Wellcome Trust Centre for
Human Genetics, Roosevelt Drive, Oxford OX3 7LJ, UK; Jianjun Gao: Epidemiology
Branch, National Institute of Environmental Health Sciences, National Institutes of
Health, North Carolina, USA; Michelle Gardner: Department of Molecular
Neuroscience, UCL Institute of Neurology, Queen Square, London, WC1N 3BG;
Raphael Gibbs: Laboratory of Neurogenetics. National Institute on Aging, National
Institutes of Health, Bethesda, MD 20892, USA, Department of Molecular
Neuroscience, UCL Institute of Neurology, Queen Square, London, WC1N 3BG;
Alison Goate: Department of Psychiatry, Department of Neurology, Washington
University School of Medicine, St. Louis, Missouri, USA; Emma Gray: Wellcome Trust
Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge CB10 1SA,
UK; Rita Guerreiro: Department of Molecular Neuroscience, UCL Institute of
Neurology, Queen Square, London, WC1N 3BG; Ómar Gústafsson: deCODE genetics,
Sturlugata 8, IS-101 Reykjavik, Iceland; Clare Harris: University of Aberdeen, Division
of Applied Health Sciences, Population Health Section, Polwarth building,
Foresterhill, Aberdeen, AB25 2ZD; Garrett Hellenthal: Wellcome Trust Centre for
Human Genetics, Roosevelt Drive, Oxford OX3 7LJ, UK; Jacobus J van Hilten:
Department of Neurology, Leiden University Medical Center, Leiden, The
Netherlands; Albert Hofman: Department of Epidemiology, Erasmus University
Medical Center, Rotterdam, The Netherlands; Albert Hollenbeck: AARP, Washington
DC, USA; Janice Holton: Queen Square Brain Bank for Neurological Disorders,
Institute of Neurology, University College London, London, UK; Michele Hu:
Department of Clinical Neurology, West Wing, Level 3, John Radcliffe Hospital,
Headley Way, Oxford OX3 9DU; Xuemei Huang : Departments of Neurology,
Radiology, Neurosurgery, Pharmacology, Kinesiology & Bioengineering, Pennsylvania
State University-Milton S. Hershey Medical Center, Hershey, Pennsylvania; Heiko
Huber: Department for Neurodegenerative Diseases, Hertie Institute for Clinical Brain
Research, University of Tübingen, and DZNE, German Center for Neurodegenerative
Diseases, Tübingen, Germany; Gavin Hudson: Neurology M4104, The Medical
School, Framlington Place, Newcastle upon Tyne, NE2 4HH UK; Sarah E Hunt:
Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton,
Cambridge CB10 1SA, UK; Johanna Huttenlocher: deCODE genetics, Sturlugata 8,
IS-101 Reykjavik, Iceland; Thomas Illig : Institute of Epidemiology, Helmholtz
Zentrum München, German Research Centre for Environmental Health, Neuherberg,
Germany; Pálmi V Jónsson: Department of Geriatrics, Landspítali University Hospital,
Reykjavík, Iceland; Cordelia Langford: Cambridge Centre for Brain Repair, Forvie Site,
Robinson Way, Cambridge CB22PY, UK; Andrew Lees: Queen Square Brain Bank for
Neurological Disorders, Institute of Neurology, University College London, London,
UK; Peter Lichtner: Institute of Human Genetics, Helmholtz Zentrum München,
German Research Centre for Environmental Health, Neuherberg, Germany; Patricia
Limousin: Institute of Neurology, Sobell Department, Unit of Functional
Neurosurgery, Queen Square, London, UK; Grisel Lopez: Section on Molecular
Neurogenetics, Medical Genetics Branch, NHGRI, National Institutes of Health,
Bethesda, Maryland, USA; Delia Lorenz: Klinik für Neurologie, Universitätsklinikum
Schleswig-Holstein, Campus Kiel, Christian-Albrechts-Universität Kiel, Kiel, Germany;
Alisdair McNeill: Department of Clinical Neurosciences, UCL Institute of Neurology,
Royal Free Campus, Rowland Hill Street, London NW3 2PF; Catriona Moorby: School
of Clinical and Experimental Medicine, University of Birmingham, Edgbaston,
Birmingham B15 2TT; Matthew Moore, Laboratory of Neurogenetics. National
Institute on Aging, National Institutes of Health, Bethesda, MD 20892, USA; Huw
Morris: MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University
School of Medicine, Cardiff, CF14 4XN, UK; Karen E Morrison: School of Clinical
and Experimental Medicine, University of Birmingham, Edgbaston, Birmingham B15
2TT, Neurosciences Department, Queen Elizabeth Hospital, University Hospitals
670 Klebe S, et al. J Neurol Neurosurg Psychiatry 2013;84:666–673. doi:10.1136/jnnp-2012-304475
Movement disorders
 group.bmj.com on June 6, 2013 - Published by jnnp.bmj.comDownloaded from 
Birmingham NHS Foundation Trust, Birmingham B15 2TH; Ese Mudanohwo:
Neurogenetics Unit, UCL Institute of Neurology/National Hospital for Neurology and
Neurosurgery, Queen Square, London, UK; Sean S O’Sullivan: Queen Square Brain
Bank for Neurological Disorders, Institute of Neurology, University College London,
London, UK; Justin Pearson: MRC Centre for Neuropsychiatric Genetics and
Genomics, Cardiff University School of Medicine, Cardiff, CF14 4XN, UK; Richard
Pearson: Wellcome Trust Centre for Human Genetics, Roosevelt Drive, Oxford OX3
7LJ, UK; Joel S Perlmutter: Department of Psychiatry, Department of Neurology,
Washington University School of Medicine, St. Louis, Missouri, USA; Hjörvar
Pétursson: deCODE genetics, Sturlugata 8, IS-101 Reykjavik, Iceland, Department of
Medical Genetics, Institute of Human Genetics, University of Tübingen, Tübingen,
Germany; Matti Pirinen: Wellcome Trust Centre for Human Genetics, Roosevelt Drive,
Oxford OX3 7LJ, UK; Pierre Pollak: Service de Neurologie, CHU de Grenoble,
Grenoble, France; Bart Post: Department of Neurology, Radboud University Nijmegen
Medical Centre, Nijmegen, The Netherlands; Simon Potter: Wellcome Trust Sanger
Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge CB10 1SA, UK;
Bernard Ravina: Translational Neurology, Biogen Idec, 14 Cambridge Center, Bio 6,
Cambridge, Massachusetts, USA; Tamas Revesz: Queen Square Brain Bank for
Neurological Disorders, Institute of Neurology, University College London, London,
UK; Olaf Riess: Department of Medical Genetics, Institute of Human Genetics,
University of Tübingen, Tübingen, Germany; Fernando Rivadeneira: Department of
Epidemiology, Erasmus University Medical Center, Rotterdam, The Netherlands,
Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The
Netherlands; Patrizia Rizzu: Department of Clinical Genetics, Section of Medical
Genomics, VU University Medical Centre, Amsterdam, The Netherlands; Mina Ryten:
Department of Molecular Neuroscience, UCL Institute of Neurology, Queen Square,
London, WC1N 3BG; Stephen Sawcer: University of Cambridge, Department of
Clinical Neurosciences, Addenbrooke’s hospital, Hills Road, Cambridge, CB2 0QQ,
UK; Anthony Schapira: Department of Clinical Neurosciences, UCL Institute of
Neurology, Royal Free Campus, Rowland Hill Street, London NW3 2PF; Hans
Scheffer: Department of Human Genetics, Radboud University Nijmegen Medical
Centre, Nijmegen, The Netherlands; Karen Shaw: Queen Square Brain Bank for
Neurological Disorders, Institute of Neurology, University College London, London,
UK; Ira Shoulson: Department of Neurology, University of Rochester, Rochester,
New York 14620, USA; Ellen Sidransky: Section on Molecular Neurogenetics,
Medical Genetics Branch, NHGRI, National Institutes of Health, Bethesda, Maryland,
USA; Rohan de Silva: Department of Molecular Neuroscience, UCL Institute of
Neurology, Queen Square, London, WC1N 3BG; Colin Smith: Department of
Pathology, Wilkie Building, Teviot Place, Edinburgh, EH8 9AG; Chris CA Spencer:
Wellcome Trust Centre for Human Genetics, Roosevelt Drive, Oxford OX3 7LJ, UK;
Hreinn Stefánsson: deCODE genetics, Sturlugata 8, IS-101 Reykjavik, Iceland; Stacy
Steinberg: deCODE genetics, Sturlugata 8, IS-101 Reykjavik, Iceland; Joanna D
Stockton: School of Clinical and Experimental Medicine, University of Birmingham,
Edgbaston, Birmingham B15 2TT; Amy Strange: Wellcome Trust Centre for Human
Genetics, Roosevelt Drive, Oxford OX3 7LJ, UK; Zhan Su: Wellcome Trust Centre for
Human Genetics, Roosevelt Drive, Oxford OX3 7LJ, UK; Kevin Talbot: University of
Oxford, Department of Clinical Neurology, John Radcliffe Hospital, Oxford OX3 9DU;
Carlie M Tanner: Clinical Research Department, The Parkinson’s Institute and Clinical
Center, Sunnyvale, California, USA; Avazeh Tashakkori-Ghanbaria: Wellcome Trust
Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge CB10 1SA,
UK; François Tison: Service de Neurologie, Hôpital Haut-Lévêque, Pessac, France;
Daniah Trabzuni: Department of Molecular Neuroscience, UCL Institute of Neurology,
Queen Square, London, WC1N 3BG; Bryan J Traynor: Laboratory of Neurogenetics.
National Institute on Aging, National Institutes of Health, Bethesda, MD 20892,
USA; André G Uitterlinden: Department of Epidemiology, Erasmus University Medical
Center, Rotterdam, The Netherlands, Department of Internal Medicine, Erasmus
Medical Center, Rotterdam, The Netherlands; Jana Vandrovcova: Department of
Molecular Neuroscience, UCL Institute of Neurology, Queen Square, London, WC1N
3BG; Daan Velseboer: Department of Neurology, Academic Medical Center,
University of Amsterdam, Amsterdam, The Netherlands; Marie Vidailhet: INSERM,
UMR_S975 (Formerly UMR_S679), Paris, France, Université Pierre et Marie
Curie-Paris, Centre de Recherche de l’Institut du Cerveau et de la Moelle épinière,
UMR-S975, Paris, France, CNRS, UMR 7225, Paris, France; Damjan Vukcevic:
Wellcome Trust Centre for Human Genetics, Roosevelt Drive, Oxford OX3 7LJ, UK;
Robert Walker: Department of Pathology, Wilkie Building, Teviot Place, Edinburgh,
EH8 9AG; Bart van de Warrenburg: Department of Neurology, Radboud University
Nijmegen Medical Centre, Nijmegen, The Netherlands; Michael E Weale: King’s
College London, Department of Medical and Molecular Genetics, London SE1 9RT;
Mirdhu Wickremaratchi: Department of Neurology, Cardiff University, Cardiff, UK;
Nigel Williams: MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff
University School of Medicine, Cardiff, CF14 4XN, UK; Caroline H Williams-Gray:
Department of Neurology, Addenbrooke’s Hospital, University of Cambridge, Hills
Road, Cambridge CB2 2QQ; Sophie Winder-Rhodes: Department of Psychiatry and
Medical Research Council/Wellcome Trust Behavioural and Clinical Neurosciences
Institute, University of Cambridge, Cambridge, UK; Kári Stefánsson, deCODE
genetics, Sturlugata 8, IS-101 Reykjavik, Iceland; Maria Martinez: INSERM UMR
1043, CPTP, Toulouse, France, Paul Sabatier University, Toulouse, France; Peter
Donnelly: Wellcome Trust Centre for Human Genetics, Roosevelt Drive, Oxford OX3
7LJ, UK; John Hardy: Department of Molecular Neuroscience, UCL Institute of
Neurology, Queen Square, London, WC1N 3BG; Peter Heutink: Department of
Clinical Genetics, Section of Medical Genomics, VU University Medical Centre,
Amsterdam, The Netherlands; Alexis Brice: INSERM, UMR_S975 (Formerly
UMR_S679), Paris, France, Université Pierre et Marie Curie-Paris, Centre de
Recherche de l’Institut du Cerveau et de la Moelle épinière, UMR-S975, Paris,
France, CNRS, UMR 7225, Paris, France, AP-HP, Pitié-Salpêtrière Hospital,
Department of Genetics and Cytogenetics, Paris, France; Thomas Gasser:
Department for Neurodegenerative Diseases, Hertie Institute for Clinical Brain
Research, University of Tübingen, and DZNE, German Center for Neurodegenerative
Diseases, Tübingen, Germany; Nicholas W Wood: UCL Genetics Institute, Gower
Place, London, WC1E 6BT, UK, Department of Molecular Neuroscience, UCL
Institute of Neurology, Queen Square, London, WC1N 3BG; Andrew B Singleton:
Laboratory of Neurogenetics. National Institute on Aging, National Institutes of
Health, Bethesda, MD 20892, USA.
Contributors SK drafting/revising the manuscript, study concept or design, analysis
or interpretation of data, acquisition of data. JLG drafting/revising the manuscript,
study concept or design, analysis or interpretation of data. MAN drafting/revising the
manuscript, study concept or design, analysis or interpretation of data, acquisition of
data. GK drafting/revising the manuscript and interpretation of data. RC revising the
manuscript and analysis or interpretation of data. AB drafting/revising the
manuscript, study concept or design, analysis or interpretation of data, acquisition of
data. JCC drafting/revising the manuscript, study concept or design, analysis or
interpretation of data, acquisition of data. GK, DL and GD were responsible for
patient characterisation and sample collection of the Kiel sample. CK and JH were
responsible for patient characterisation and sample collection of the Lübeck sample.
TG and IW were responsible for patient characterisation and sample collection of the
Tübingen sample. MAN, ABS, JMB, JHy, JSS, PH were responsible for patient
characterisation and sample collection of the International Parkinson’s Disease
Genomics Consortium. SK, JCC, AB, SL, MS, MM, FD, PP, PD, FT, AD and MV were
responsible for patient characterisation and sample collection of the French sample.
PA, JCL, CT and CM were responsible for the 3C sample collection. FCB, KT assisted
in experimental design and execution. All authors critically reviewed the manuscript.
Funding IPDGC: This US work was supported in part by the Intramural Research
Programs of the National Institute on Aging, National Institute of Neurological
Disorders and Stroke, National Institute of Environmental Health Sciences, National
Human Genome Research Institute, National Institutes of Health, Department of
Health and Human Services; project numbers Z01 AG000949-02 and
Z01-ES101986. In addition this study was supported by the US Department of
Defense, award number W81XWH-09-2-0128. Funding to support collection of a
portion of the samples was obtained from the National Institutes of Health (grants
NS057105 and RR024992), the American Parkinson Disease Association (APDA),
Barnes Jewish Hospital Foundation and the Greater St Louis Chapter of the APDA.
This work was supported in part by the Wellcome Trust/MRC Joint Call in
Neurodegeneration award (WT089698) to the UK Parkinson’s Disease Consortium
(UKPDC) whose members are from the UCL/Institute of Neurology, the University of
Shefﬁeld and the MRC Protein Phosphorylation Unit at the University of Dundee.
Additionally part of the study was undertaken at UCLH/UCL using funding through a
Department of Health NIHR Biomedical Research Centre. This work was also
supported by Parkinson’s UK (Grants 8047 and J-0804) and the Medical Research
Council (G0700943). Genotyping of UK replication cases on Immunochip was part
of the Wellcome Trust Case Control Consortium 2 project which is funded by the
Wellcome Trust (085475/B/08/Z and 085475/Z/08/Z). PD is partly supported by a
Wolfson-Royal Society Merit award. The UK gene expression work was supported in
part by the UK Medical Research Council (G0901254) to researchers based in the
UCL Institute of Neurology and King’s College London. JH receives support from the
Reta Lila Weston Trust for Medical Research. This work was also supported by the
Landspitali University Hospital Research Fund (S.Sv.), the Icelandic Research Council
(S.Sv.), the European Community Framework Programme 7, People programme, IAPP
on novel genetic and phenotypic markers of Parkinson’s disease and Essential
Tremor (Mark MD), contract no PIAP-GA-2008-230596 MarkMD. (H Petursson, J
Holton). The KORA research platform (KORA: Cooperative Research in the Region of
Augsburg; http://www.gsf.de/KORA) was initiated and ﬁnanced by the
ForschungszentrumfürUmwelt und Gesundheit (GSF), which is funded by the
German Federal Ministry of Education, Science, Research and Technology and by the
State of Bavaria. The study was additionally funded by the German National
Genome Network (NGFNplus #01GS08134; German Ministry for Education and
Research) and in addition by the German Federal Ministry of Education and Research
(BMBF) NGFN (01GR0468) and in the frame of ERA-Net NEURON (01GW0908).
This work was also supported by the Helmholtz Alliance Mental Health in an Ageing
Society (HelMA, HA-215) funded by the Initiative and Networking Fund of the
Helmholtz Association. The French GWA scan work was supported by the French
National Agency of Research (http://www.agence-nationale-recherche.fr,
ANR-08-MNP-012) and by the National Research Funding Agency
(ANR-08-NEUR-004-01) in ERA-NET NEURON framework (http://www.
neuron-eranet.eu). We also want to thank the Hersenstichting Nederland (http://
www.hersenstichting.nl), the Neuroscience Campus Amsterdam and the section of
Klebe S, et al. J Neurol Neurosurg Psychiatry 2013;84:666–673. doi:10.1136/jnnp-2012-304475 671
Movement disorders
 group.bmj.com on June 6, 2013 - Published by jnnp.bmj.comDownloaded from 
Medical genomics, the Prinses Beatrix Fonds (http://www.prinsesbeatrixfonds.nl) for
sponsoring this work. This study utilised the high-performance computational
capabilities of the Biowulf Linux cluster at the National Institutes of Health,
Bethesda, Md. (http://biowulf.nih.gov). DNA panels and samples from the NINDS
Human Genetics Resource Center DNA and Cell Line Repository (http://ccr.coriell.org/
ninds) were used in this study, as well as clinical data. The submitters that
contributed samples are acknowledged in detailed descriptions of each panel
(http://ccr.coriell.org/sections/Collections/NINDS/?SsId=10). The authors thank The
French Parkinson’s Disease Genetics Study Group: Y Agid, M Anheim, A-M Bonnet,
M Borg, A Brice, E Broussolle, J-C Corvol, Ph Damier, A Destée, A Dürr, F Durif,
S Klebe, E Lohmann, M Martinez, P Pollak, O Rascol, F Tison, C Tranchant, M
Vérin, F Viallet and M Vidailhet. The authors thank the members of the French 3C
consortium: Drs Annick Alpérovitch, Claudine Berr, Christophe Tzourio and
Jean-Charles Lambert for giving us the possibility to use part of the 3C cohort; and
Drs M Lathrop and D Zelenika for their support in generating the genome-wide
molecular data. The UK brain samples for the gene expression studies were obtained
from the MRC Sudden Death Brain Bank in Edinburgh. This study makes use of
GWA data generated by the Wellcome Trust Case-Control consortium 2 (WTCCC2)
on UK PD cases and on UK controls from the 1958 Birth Cohort (58BC) and
National Blood Service (NBS). UK population control data was made available
through WTCCC1. We thank Jeffrey Barrett for assistance with the design of the
Immunochip.
Competing interests None.
Ethics approval Local ethics committees.
Disclosure Dr Klebe received funding from the Deutsche Forschungsgemeinschaft
(DFG) (DFG Kl 1433/2-1). He received royalties from Thieme publishers. Dr Golmard
reports no disclosures. Dr Nalls reports no disclosures. Dr Martinez reports no
disclosures. Prof Singleton reports no disclosures. Dr Bras reports no disclosures.
Prof. Hardy consults for Eisai Pharmaceuticals. Dr Javier Simon-Sanchez reports no
disclosures. Dr Peter Heutink reports no disclosures. Prof Kuhlenbäumer received
grants from the Deutsche Forschungsgemeinschaft (DFG), the regional government
and the Christian-Albrechts-University Kiel. Prof Klein is supported by grants from
the Hermann and Lilly Schilling Foundation and from the BMBF (01GI0201), and the
Bachmann-Strauss Dystonia & Parkinson Foundation. She also received consulting
fees from Centogene and honoraria for speaking from Shire and Merz Pharma. Dr
Charﬁ reports no disclosures. Dr Johann Hagenah receives funding
Bachmann-Strauss Dystonia Parkinson. Prof Gasser serves as an editorial board
member of Parkinsonism and Related Disorders, Journal of Parkinson’s Disease and
Neurogenetics and is funded by Novartis Pharma, the Federal Ministry of Education
and Research (BMBF) (NGFN-Plus and ERA-Net NEURON), the Helmholtz
Association (HelMA, Helmholtz Alliance for Health in an Ageing Society) and the
European Community (MeFoPa, Mendelian Forms of Parkinsonism). He received
speakers’ honoraria from Novartis, Merck-Serono, Schwarz Pharma, Boehringer
Ingelheim and Valeant Pharma and royalties for his consulting activities from
Cefalon Pharma and Merck-Serono. Prof. Gasser holds a patent concerning the
LRRK2 gene and neurodegenerative disorders. I Wurster reports funding by
GlaxoSmithKline for travel to a Congress. no disclosures. Dr Lesage reports no
disclosures. Dr Lorenz reports no disclosures. Prof Deuschl has received lecture fees
from Orion, Lundbeck, Teva and Pﬁzer and has been serving as a consultant for
TEVA. He received royalties from Thieme publishers. He is a government employee
and he receives through his institution funding for his research from the German
Research Council, the German Ministery of Education and Health and Medtronic. Dr
Saad reports no disclosures. Prof Durif reports no disclosures. Prof Pollak received
speaker honoraria for from Novartis and Medtronic. Prof Damier served on the
European advisory board for Lundbeck-Teva and received honoraria for conferences
given on behalf Novartis and Glaxo SmithKline. Prof Tison has received speaker
honoraria from UCB, Novartis, Lundbeck, GSK, Boehringer Ingelheim and Aguettant;
served on scientiﬁc advisory board for Novartis, Addex pharmaceuticals; received
research grant from Novartis and received funding for travel from Novartis, UCB,
Lunbeck. Dr Durr received honoraria from Pﬁzer Inc. for participating to the Global
TTR FAP Genetics Advisory Board, and received research support for the French
Agency for Research. Dr Maubaret is funded by the foundation ‘Pour la recherché
médicale’ (FRM, France) and reports no disclosures. Dr Amouyel received honoraria
from serving on the medical advisory board of Total and Ipsen, for lectures for
Sanoﬁ, Pﬁzer, Servier and holds stocks from Genoscreen. Dr Lambert reports no
disclosures. Dr Tzourio reports no disclosures. Dr Charbonnier-Beaupel reports no
disclosures. Ms Tahiri reports no disclosures. Prof Vidailhet had institutional (ANR,
DHOS-INSERM) and Patient’s association (France Parkinson) research grants. Prof
Brice received honoraria from the Wolfson Foundation for reviewing scientiﬁc project,
and received research support from the French Agency for Research, Programme
Hospitalier de Recherche Clinique, European Community and patients associations.
Dr Jean-Christophe Corvol received research grants from INSERM and APHP, and
received speaker’s honoraria and travel reimbursements from Lundbeck, Biogen and
Schering-Plough.
Provenance and peer review Not commissioned; externally peer reviewed.
Open Access This is an Open Access article distributed in accordance with the
Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which
permits others to distribute, remix, adapt, build upon this work non-commercially, and
license their derivative works on different terms, provided the original work is properly
cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/
3.0/
REFERENCES
1 Floderus Y, Wetterberg L. The inheritance of human erythrocyte
catechol-O-methyltransferase activity. Clin Genet 1981;19:392–5.
2 Weinshilboum R, Raymond F. Variations in catechol-O-methyltransferase activity in
inbred strains of rats. Neuropharmacology 1977;16:703–6.
3 Lotta T, Vidgren J, Tilgmann C, et al. Kinetics of human soluble and
membrane-bound catechol O-methyltransferase: a revised mechanism and
description of the thermolabile variant of the enzyme. Biochemistry
1995;34:4202–10.
4 Lachman HM, Papolos DF, Saito T, et al. Human catechol-O-methyltransferase
pharmacogenetics: description of a functional polymorphism and its potential
application to neuropsychiatric disorders. Pharmacogenetics 1996;6:243–50.
5 McLeod HL, Syvanen AC, Githang’a J, et al. Ethnic differences in catechol
O-methyltransferase pharmacogenetics: frequency of the codon 108/158 low activity
allele is lower in Kenyan than Caucasian or South-west Asian individuals.
Pharmacogenetics 1998;8:195–9.
6 Hernan MA, Checkoway H, O’Brien R, et al. MAOB intron 13 and COMT codon
158 polymorphisms, cigarette smoking, and the risk of PD. Neurology
2002;58:1381–7.
7 Eerola J, Launes J, Hellstrom O, et al. Apolipoprotein E (APOE), PARKIN and
catechol-O-methyltransferase (COMT) genes and susceptibility to sporadic
Parkinson’s disease in Finland. Neurosci Lett 2002;330:296–8.
8 Foltynie T, Goldberg TE, Lewis SG, et al. Planning ability in Parkinson’s disease is
inﬂuenced by the COMT val158met polymorphism. Mov Disord 2004;19:885–91.
9 Hoogland J, de Bie RM, Williams-Gray CH, et al. Catechol-O-methyltransferase
val158met and cognitive function in Parkinson’s disease. Mov Disord
2010;25:2550–4.
10 Rissling I, Frauscher B, Kronenberg F, et al. Daytime sleepiness and the COMT
val158met polymorphism in patients with Parkinson disease. Sleep
2006;29:108–11.
11 Williams-Gray CH, Hampshire A, Robbins TW, et al. Catechol O-methyltransferase
Val158Met genotype inﬂuences frontoparietal activity during planning in patients
with Parkinson’s disease. J Neurosci 2007;27:4832–8.
12 Hughes AJ, Daniel SE, Kilford L, et al. Accuracy of clinical diagnosis of idiopathic
Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg
Psychiatry 1992;55:181–4.
13 3C Study Group. Vascular factors and risk of dementia: design of the Three-City
Study and baseline characteristics of the study population. Neuroepidemiology
2003;22:316–25 .
14 Krawczak M, Nikolaus S, von Eberstein H, et al. PopGen: population-based
recruitment of patients and controls for the analysis of complex genotype-phenotype
relationships. Community Genet 2006;9:55–61.
15 Nalls MA, Plagnol V, Hernandez DG, et al. Imputation of sequence variants for
identiﬁcation of genetic risks for Parkinson’s disease: a meta-analysis of
genome-wide association studies. Lancet 2011;377:641–9.
16 International Parkinson's Disease Genomics Consortium (IPDGC); Wellcome Trust
Case Control Consortium 2 (WTCCC2). A two-stage meta-analysis identiﬁes several
new loci for Parkinson’s disease. PLoS Genet 2011;7:e1002142.
17 Simon-Sanchez J, Schulte C, Bras JM, et al. Genome-wide association study reveals
genetic risk underlying Parkinson’s disease. Nat Genet 2009;41:1308–12.
18 Simon-Sanchez J, van Hilten JJ, van de Warrenburg B, et al. Genome-wide
association study conﬁrms extant PD risk loci among the Dutch. Eur J Hum Genet
2011;19:655–61.
19 Spencer CC, Plagnol V, Strange A, et al. Dissection of the genetics of Parkinson’s
disease identiﬁes an additional association 5’ of SNCA and multiple associated
haplotypes at 17q21. Hum Mol Genet 2011;20:345–53.
20 Saad M, Lesage S, Saint-Pierre A, et al. Genome-wide association study conﬁrms
BST1 and suggests a locus on 12q24 as the risk loci for Parkinson’s disease in the
European population. Hum Mol Genet 2011;20:615–27.
21 1000 Genomes Project Consortium, Abecasis GR, Altshuler D, et al. A map of human
genome variation from population-scale sequencing. Nature 2010;467:1061–73.
22 Li Y, Willer CJ, Ding J, et al. MaCH: using sequence and genotype data to
estimate haplotypes and unobserved genotypes. Genet Epidemiol 2010;34:
816–34.
23 Price AL, Patterson NJ, Plenge RM, et al. Principal components analysis corrects for
stratiﬁcation in genome-wide association studies. Nat Genet 2006;38:904–9.
24 Purcell S, Neale B, Todd-Brown K, et al. PLINK: a tool set for whole-genome
association and population-based linkage analyses. Am J Hum Genet
2007;81:559–75.
672 Klebe S, et al. J Neurol Neurosurg Psychiatry 2013;84:666–673. doi:10.1136/jnnp-2012-304475
Movement disorders
 group.bmj.com on June 6, 2013 - Published by jnnp.bmj.comDownloaded from 
25 Goudreau JL, Maraganore DM, Farrer MJ, et al. Case-control study of dopamine
transporter-1, monoamine oxidase-B, and catechol-O-methyl transferase
polymorphisms in Parkinson’s disease. Mov Disord 2002;17:1305–11.
26 Hoda F, Nicholl D, Bennett P, et al. No association between Parkinson’s disease
and low-activity alleles of catechol O-methyltransferase. Biochem Biophys Res
Commun 1996;228:780–4.
27 Kalinderi K, Fidani L, Kourtesi G, et al. No association of the Val158Met COMT
polymorphism with Parkinson’s disease in the Greek population. Eur J Neurol
2008;15:e83.
28 Goldman-Rakic PS, Muly EC III, Williams GV. D(1) receptors in prefrontal cells and
circuits. Brain Res Brain Res Rev 2000;31:295–301.
29 Williams-Gray CH, Hampshire A, Barker RA, et al. Attentional control in
Parkinson’s disease is dependent on COMT val 158 met genotype. Brain
2008;131:397–408.
30 Tunbridge EM, Harrison PJ, Weinberger DR. Catechol-o-methyltransferase, cognition,
and psychosis: Val158Met and beyond. Biol Psychiatry 2006;60:141–51.
31 Corvol JC, Bonnet C, Charbonnier-Beaupel F, et al. The COMT Val158Met
polymorphism affects the response to entacapone in Parkinson’s disease: a
randomized crossover clinical trial. Ann Neurol 2011;69:111–18.
32 Contin M, Martinelli P, Mochi M, et al. Genetic polymorphism of
catechol-O-methyltransferase and levodopa pharmacokinetic-pharmacodynamic
pattern in patients with Parkinson’s disease. Mov Disord 2005;20:734–9.
33 Denys D, Van Nieuwerburgh F, Deforce D, et al. Association between the dopamine
D2 receptor TaqI A2 allele and low activity COMT allele with obsessive-compulsive
disorder in males. Eur Neuropsychopharmacol 2006;16:446–50.
34 Poyurovsky M, Michaelovsky E, Frisch A, et al. COMT Val158Met polymorphism in
schizophrenia with obsessive-compulsive disorder: a case-control study. Neurosci
Lett 2005;389:21–4.
35 Pooley EC, Fineberg N, Harrison PJ. The met(158) allele of
catechol-O-methyltransferase (COMT) is associated with obsessive-compulsive
disorder in men: case-control study and meta-analysis. Mol Psychiatry
2007;12:556–61.
36 Chen J, Lipska BK, Halim N, et al. Functional analysis of genetic variation
in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and
enzyme activity in postmortem human brain. Am J Hum Genet
2004;75:807–21.
37 Gogos JA, Morgan M, Luine V, et al. Catechol-O-methyltransferase-deﬁcient mice
exhibit sexually dimorphic changes in catecholamine levels and behavior. Proc Natl
Acad Sci USA 1998;95:9991–6.
38 Harrison PJ, Tunbridge EM. Catechol-O-methyltransferase (COMT): a gene
contributing to sex differences in brain function, and to sexual dimorphism in the
predisposition to psychiatric disorders. Neuropsychopharmacology
2008;33:3037–45.
39 Tunbridge EM, Weickert CS, Kleinman JE, et al. Catechol-o-methyltransferase
enzyme activity and protein expression in human prefrontal cortex across the
postnatal lifespan. Cereb Cortex 2007;17:1206–12.
40 Bjornerem A, Straume B, Midtby M, et al. Endogenous sex hormones in relation to
age, sex, lifestyle factors, and chronic diseases in a general population: the Tromso
Study. J Clin Endocrinol Metab 2004;89:6039–47.
41 Kaminsky Z, Wang SC, Petronis A. Complex disease, gender and epigenetics. Ann
Med 2006;38:530–44.
42 Volchegorskii IA, Shemyakov SE, Turygin VV, et al. Comparative analysis of
age-related changes in activities of monoamine oxidase-B and antioxidant
defense enzymes in various structures of human brain. Bull Exp Biol Med
2001;132:760–2.
43 Launay JM, Del Pino M, Chironi G, et al. Smoking induces long-lasting effects
through a monoamine-oxidase epigenetic regulation. PLoS One 2009;4:e7959.
44 Gao X, Scott WK, Wang G, et al. Gene-gene interaction between FGF20 and MAOB
in Parkinson disease. Ann Hum Genet 2008;72:157–62.
45 Wu RM, Cheng CW, Chen KH, et al. The COMT L allele modiﬁes the association
between MAOB polymorphism and PD in Taiwanese. Neurology 2001;56:375–82.
46 Nichols WC, Pankratz N, Marek DK, et al. Mutations in GBA are associated with
familial Parkinson disease susceptibility and age at onset. Neurology
2009;72:310–16.
Klebe S, et al. J Neurol Neurosurg Psychiatry 2013;84:666–673. doi:10.1136/jnnp-2012-304475 673
Movement disorders
 group.bmj.com on June 6, 2013 - Published by jnnp.bmj.comDownloaded from 
doi: 10.1136/jnnp-2012-304475
online February 13, 2013
 2013 84: 666-673 originally publishedJ Neurol Neurosurg Psychiatry
 
Stephan Klebe, Jean-Louis Golmard, Michael A Nalls, et al.
 
disease with a sexual dimorphism
modifier of the age at onset in Parkinson's 
The Val158Met COMT polymorphism is a
 http://jnnp.bmj.com/content/84/6/666.full.html
Updated information and services can be found at: 
These include:
References
 http://jnnp.bmj.com/content/84/6/666.full.html#ref-list-1
This article cites 46 articles, 11 of which can be accessed free at:
Open Access
http://creativecommons.org/licenses/by-nc/3.0/legalcode
http://creativecommons.org/licenses/by-nc/3.0/ and 
compliance with the license. See:
work is properly cited, the use is non commercial and is otherwise in 
use, distribution, and reproduction in any medium, provided the original
Creative Commons Attribution Non-commercial License, which permits 
This is an open-access article distributed under the terms of the
service
Email alerting
the box at the top right corner of the online article.
Receive free email alerts when new articles cite this article. Sign up in
Collections
Topic
 (516 articles)Parkinson's disease   
 (1444 articles)Drugs: CNS (not psychiatric)   
 (62 articles)Open access   
 
Articles on similar topics can be found in the following collections
Notes
 http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
 http://journals.bmj.com/cgi/reprintform
To order reprints go to:
 http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
 group.bmj.com on June 6, 2013 - Published by jnnp.bmj.comDownloaded from 
